
Discover how Dr. Smita Agarwal expanded her refractive portfolio with ZEISS SMILE pro for hyperopia, and why this flapless approach delivered excellent outcomes for her first hyperopic patient.

Discover how Dr. Smita Agarwal expanded her refractive portfolio with ZEISS SMILE pro for hyperopia, and why this flapless approach delivered excellent outcomes for her first hyperopic patient.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

Prof. Dr. Luís Abegão Pinto outlines how real-world datasets can improve artificial intelligence accuracy, reduce bias, and support clinical decision-making at scale.

A study reveals varying shear-thinning behaviors in artificial tears, highlighting the importance of mimicking natural tear properties for effective eye lubrication.

Ahead of the 2nd International Glaucoma Symposium in Mainz, Germany, Stephan Schulz of Heidelberg Engineering outlines how the program blends everyday clinical challenges with advances in AI, imaging, and surgery.

Expected in the US in Q2 2026, YUVEZZI from Tenpoint Therapeutics is the first fixed-dose combination eye drop formulated to enhance near vision via pupil modulation with once-daily use.

Sakigake designation is Japan’s “premier fast-track regulatory program for innovative therapies addressing serious unmet medical needs, designed to accelerate patient access to breakthrough treatments.

US and international glaucoma specialists will converge in Mainz, Germany, on 31 January 2026, to map the next era of glaucoma care—covering AI diagnostics, optic neuropathy evaluation, and modern surgical approaches.

At the 2nd International Glaucoma Symposium on 31 January 2026, leading clinicians and researchers will share cutting-edge insights on modern surgical techniques, optic neuropathy assessment, and artificial intelligence-driven diagnostics.

Over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

A recent study reveals that retinal microvascular changes in thyroid eye disease reflect disease activity, offering potential for improved diagnostics and treatment strategies.

Researchers uncover a DNA repair mechanism in Greenland sharks that preserves their vision for centuries, offering insights into longevity and eye health.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

Positive findings in a gene therapy trial for patients with Leber Congenital Amaurosis Type 5.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

A shift toward minimally invasive, evidence-based interventions is redefining standards of care.

Navigating the labyrinth of IRD research to identify objective, clinically meaningful outcomes.

Real-world insights guide the way to tailored treatment.

The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.

Isocyclosporin is a dual inhibitor of transient receptor potential cation channel, mucolipin subfamily, member 2 (TRPML2), and calcineurin.

AI revolutionizes retinal care, enhancing diagnosis, monitoring, and treatment through innovative technologies and collaborative efforts in ophthalmology.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

Explore the challenges and insights in long-term follow-up of paediatric gene therapy, focusing on data integrity, patient retention, and ethical considerations.


The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.


Dr. Hartnett highlights new approaches to ROP care and the changing ethical, clinical, and technological landscape in a guest lecture.

Remote monitoring of age-related macular degeneration enhances patient care, reduces treatment burden, and leverages AI for personalized management.